Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR1 | Q9Y271 | 4/20 | 0.56 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.56 |
| ▸ | CYSLTR2 | Q9NS75 | 3/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7715945 | 0.96 | CYSLTR1 (0.56) | CYSLTR1GPBAR1CYSLTR2 | |
| SCHEMBL7714758 | 0.95 | CYSLTR1 (0.60) | CYSLTR1GPBAR1CYSLTR2 | |
| SCHEMBL8107945 | 0.95 | CYSLTR1 (0.62) | CYSLTR1GPBAR1CYSLTR2 | |
| SCHEMBL10421737 | 0.94 | CYSLTR1 (0.58) | CYSLTR1GPBAR1CYSLTR2 | |
| SCHEMBL10420346 | 0.93 | CYSLTR1 (0.60) | CYSLTR1GPBAR1CYSLTR2 | |
| SCHEMBL6088661 | 0.93 | CYSLTR1 (0.53) | CYSLTR1GPBAR1CYSLTR2 | |
| SCHEMBL7011760 | 0.93 | CYSLTR1 (0.57) | CYSLTR1GPBAR1CYSLTR2 | |
| SCHEMBL10422068 | 0.92 | CYSLTR1 (0.56) | CYSLTR1GPBAR1CYSLTR2 | |
| SCHEMBL10421918 | 0.92 | CYSLTR1 (0.56) | CYSLTR1GPBAR1CYSLTR2 | |
| SCHEMBL9827184 | 0.92 | CYSLTR1 (0.58) | CYSLTR1GPBAR1CYSLTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6376512-B1 | FOR TREATING PHYSIOLOGICAL CONDITION IN PATIENT WHEREIN SAID CONDITION IS ASSOCIATED WITH A PHYSIOLOGICALLY DETRIMENTAL LEVELS OF INSULIN, GLUCOSE, FREE FATTY ACIDS, OR TRIGLYCERIDES | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-04-23 | — | — | US | disclosed |
| US-5059610-A | QUINOLINE DERIVATIVES AND THEIR USE AS ANTAGONISTS OF LEUKOTRIENE D4 | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1991-10-22 | — | — | US | disclosed |